https://doi.org/10.4081/reumatismo.2023.1548

Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic review

Vol. 75 No. 1 (2023)
Submitted: 2 January 2023
Accepted: 27 March 2023
Published: 8 May 2023
Myositis, COVID-19, vaccine, dermatomyositis, polymyositis
Abstract Views: 1453
PDF: 836
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

A. Camargo-Coronel
Rheumatology Department, Centro Médico Nacional Siglo XXI, Mexico City, Mexico.
H. Quiñones-Moya
horacio_qmac@gmail.com
https://orcid.org/0000-0001-5689-0872
Rheumatology Department, Centro Médico Nacional Siglo XXI, Mexico City, Mexico.
M.R. Hernández-Zavala
Rheumatology Department, Centro Médico Nacional Siglo XXI, Mexico City, Mexico.
J.R. Hernández-Vázquez
https://orcid.org/0000-0002-5270-2974
Rheumatology Department, Centro Médico Nacional Siglo XXI, Mexico City, Mexico.
M.Á. Vázquez-Zaragoza
Rheumatology Department, Centro Médico Nacional Siglo XXI, Mexico City, Mexico.

The COVID-19 pandemic represents a global health problem, which has been mitigated by the opportune introduction of vaccination programs. Although we already know the benefit that vaccines provide, these are not exempt from adverse events which can be mild to deadly, such as idiopathic inflammatory myopathies, in which a temporal association has not been defined. It is for this reason that we carried out a systematic review of all reported cases of vaccination against COVID-19 and myositis. To identify previously reported cases of idiopathic inflammatory myopathies associated with vaccination against SARS-CoV-2 we registered this protocol on the website of PROSPERO with identification number CRD42022355551. Of the 63 publications identified in MEDLINE and 117 in Scopus, 21 studies were included, reporting 31 cases of patients with vaccination-associated myositis. Most of these cases were women (61.3%); mean age was 52.3 years (range 19-76 years) and mean time of symptom onset post-vaccination was 6.8 days. More than half of the cases were associated with Comirnaty, 11 cases (35.5%) were classified as dermatomyositis, and 9 (29%) as amyopathic dermatomyositis. In 6 (19.3%) patients another probable trigger was identified. Case reports of inflammatory myopathies associated with vaccination have heterogeneous presentations without any specific characteristics: as a consequence, it is not possible to ensure a temporal association between vaccination and the development of inflammatory myopathies. Large epidemiological studies are required to determine the existence of a causal association.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021; 4: e2035057. DOI: https://doi.org/10.1001/jamanetworkopen.2020.35057
World Health Organization. Available from: https://covid19.who.int/?mapFilter=vaccinations
Butt AA, Talisa VB, Shaikh OS, Omer SB, Mayr FB. Relative vaccine effectiveness of a SARS-CoV-2 mRNA vaccine booster dose against the Omicron variant. Clin Infect Dis. 2022; 75: 2161-8. DOI: https://doi.org/10.1093/cid/ciac328
Adams K, Rhoads JP, Surie D, Gaglani M, Ginde AA, McNeal T, et al. Vaccine effectiveness of primary series and booster doses against Omicron variant COVID-19-associated hospitalization in the United States. medRxiv. 2022; doi: 10.1101/2022.06.09.22276228. DOI: https://doi.org/10.1101/2022.06.09.22276228
Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, et al. COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US states, January 2021 to April 2022. JAMA Intern Med. 2022; 182: 1071-81. DOI: https://doi.org/10.1001/jamainternmed.2022.4299
Mushtaq HA, Khedr A, Koritala T, Bartlett BN, Jain NK, Khan SA. A review of adverse effects of COVID-19 vaccines. Infez Med. 2022; 30: 1-10. DOI: https://doi.org/10.53854/liim-3001-1
Stübgen JP. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev. 2014; 13: 31-9. DOI: https://doi.org/10.1016/j.autrev.2013.08.005
Fernandez PI, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018; 20: 21. DOI: https://doi.org/10.1007/s11926-018-0732-6
Orbach H, Tanay A. Vaccines as a trigger for myopathies. Lupus. 2009; 18: 1213-6. DOI: https://doi.org/10.1177/0961203309345734
Betteridge Z, Tansley S, Shaddick G, Chinoy H, CooperRG, New RP, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019; 101: 48-55. DOI: https://doi.org/10.1016/j.jaut.2019.04.001
Chaima K, Mariem A, Sana B, Khadija S, Mariem R, Massara B, et al. Vaccine-induced dermatomyositis following COVID-19 vaccination. Dermatol Ther. 2022; 35: e15749. DOI: https://doi.org/10.1111/dth.15749
Venkateswaran K, Aw DCW, Huang J, Angkodjojo S. Dermatomyositis following COVID-19 vaccination. Dermatol Ther. 2022; 35: e15479. DOI: https://doi.org/10.1111/dth.15479
Gouda W, Albasri A, Alsaqabi F, Al Sabah HY, Alkandari M, Abdelnaby H. Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination. J Korean Med Sci. 2022; 37: e32. DOI: https://doi.org/10.3346/jkms.2022.37.e32
Holzer MT, Krusche M, Ruffer N, Haberstock H, Stephan M, Huber TB, et al. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol. 2022; 42: 2267-76. DOI: https://doi.org/10.1007/s00296-022-05176-3
Aimo C, Mariotti EB, Corr A, Quintarelli L, Bianchi B, Verdelli A, et al. Lymphedema of the arm after COVID-19 vaccination in a patient with hidden breast cancer and paraneoplastic dermatomyositis. Vaccines. 2022; 10: 1219. DOI: https://doi.org/10.3390/vaccines10081219
Magen E, Mukherjee S, Bhattacharya M, Detroja R, Merzon E, Blum I, et al. Clinical and molecular characterization of a rare case of BNT162b2 mRNA COVID-19 vaccine-associated myositis. Vaccines. 2022; 10: 1135. DOI: https://doi.org/10.3390/vaccines10071135
Camargo Coronel A, Jiménez Balderas FJ, Quiñones Moya H, Hernández Zavala MR, Mandinabeitia Rodríguez P, Hernández Vázquez JR, et al. Dermatomyositis post vaccine against SARS-COV2. BMC Rheumatol. 2022; 6: 20. DOI: https://doi.org/10.1186/s41927-022-00250-6
Huang ST, Lee TJ, Chen KH, Sun HY, Chen WT, Hsieh SC, et al. Fatal myositis, rhabdomyolysis and compartment syndrome after ChAdOx1 nCoV-19 vaccination. J Microbiol Immunol Infect. 2022; 55: 1131-3. DOI: https://doi.org/10.1016/j.jmii.2022.04.003
Vutipongsatorn K, Isaacs A, Farah Z. Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports. J Med Case Rep. 2022; 16: 57. DOI: https://doi.org/10.1186/s13256-022-03266-1
GonzalezD,GuptaL,MurthyV,GonzalezEB, Williamson KA, Makol A, et al. Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. Rheumatol Int. 2022; 42: 1629-41. DOI: https://doi.org/10.1007/s00296-022-05149-6
Wu M, Karim M, Ashinoff R. COVID-19 vaccine-associated dermatomyositis. JAAD Case Reports. 2022; 23: 58-60. DOI: https://doi.org/10.1016/j.jdcr.2022.02.023
Kim JH, Kim JH, Woo CG. Clinicopathological characteristics of inflammatory myositis induced by COVID-19 vaccine (Pfizer-BioN-Tech BNT162b2): a case report. J Korean Med Sci. 2022; 37: e91. DOI: https://doi.org/10.3346/jkms.2022.37.e91
Kondo Y, Oyama M, Nakamura Y, Matsubara S, Tanikawa A, Kaneko Y. Dermatomyositis-like rash and inflammatory myopathy after mRNA-1273 vaccination. Rheumatol. 2022; 61: e171-3. DOI: https://doi.org/10.1093/rheumatology/keac038
Lee AYS, Lee C, Brown DA, Suan D. Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination. Postgrad Med J. 2022; postgradmedj-2022-141510. DOI: https://doi.org/10.1136/postgradmedj-2022-141510
Kreuter A, Lausch S, Burmann SN, Paschos A, Michalowitz AL. Onset of amyopathic dermatomyositis following mRNA-based SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol. 2022; 36: e669-72. DOI: https://doi.org/10.1111/jdv.18211
Ooi XT, Choi EC, Lee JS. Manifestation of a cancer-associated TIF-1 gamma dermatomyositis after COVID-19 vaccine. Int J Dermatol. 2022; 61: 1425-6. DOI: https://doi.org/10.1111/ijd.16358
Durucan I, Guner S, Kilickiran Avci B, Unverengil G, Melikoglu M, Ugurlu S. Post Covıd-19 vaccınatıon inflammatory syndrome: a case report. Mod Rheumatol Case Rep. 2022; 7: 280-2. DOI: https://doi.org/10.1093/mrcr/rxac041
Tan CY, Toh TH, Toh YF, Wong KT, Shahrizaila N, Goh KJ. A temporal association between COVID-19 vaccination and immune-mediated necrotizing myopathy. Muscle Nerve. 2022; 65 (6): E24-6. DOI: https://doi.org/10.1002/mus.27531
Dodig D, Fritzler MJ, Naraghi A, Tarnopolsky MA, Lu JQ. Immune-mediated necrotizing myopathy after BNT162b2 vaccination in a patient with antibodies against receptor-binding domain of SARS-CoV-2 and signal recognition particle. Muscle Nerve. 2022; 65: E11-3. DOI: https://doi.org/10.1002/mus.27483
Gouveia J, Barros C, Caldeira M, Ferreira C, Freitas R. Inflammatory myopathy secondary to SARS-CoV-2 vaccination. Isr Med Assoc J. 2022; 24: 444.
Gupta K, Sharma GS, Kumar A. COVID-19 vaccination-associated anti-Jo-1 syndrome. Reumatologia. 2021; 59: 420-2. DOI: https://doi.org/10.5114/reum.2021.111836
Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018; 14: 269-78. DOI: https://doi.org/10.1038/nrrheum.2018.41
Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramirez R, et al. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther. 2013; 15: R48. DOI: https://doi.org/10.1186/ar4207
Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from december 2020 to august 2021. JAMA. 2022; 327: 331-40. DOI: https://doi.org/10.1001/jama.2021.24110
Hanson KE, Goddard K, Lewis N, Fireman B, Myers TR, Bakshi N, et al. Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the vaccine safety datalink. JAMA Netw Open. 2022; 5: e228879. DOI: https://doi.org/10.1001/jamanetworkopen.2022.8879
Klomjit N, Alexander MP, Fervenza FC, Zoghby Z, Garg A, Hogan MC, et al. COVID-19 vaccination and glomerulonephritis. Kidney Int Rep. 2021; 6: 2969-78. DOI: https://doi.org/10.1016/j.ekir.2021.09.008
Ding Y, Ge Y. Inflammatory myopathy following coronavirus disease 2019 vaccination: a systematic review. Front Public Health. 2022; 10: 1007637. DOI: https://doi.org/10.3389/fpubh.2022.1007637
Huang YZ, Kuan CC. Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022; 26: 1770-6.

How to Cite

Camargo-Coronel, A., Quiñones-Moya, H., Hernández-Zavala, M., Hernández-Vázquez, J., & Vázquez-Zaragoza, M. (2023). Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic review. Reumatismo, 75(1). https://doi.org/10.4081/reumatismo.2023.1548
Copyright (c) 2023 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.